Pharma channel feed

Aveo On­col­o­gy gets the long-await­ed green­light to mar­ket tivozanib — 9 years af­ter fil­ing its first NDA

5 years ago
FDA+

With prof­its lag­ging, Em­ma Walm­s­ley, Big Phar­ma's on­ly woman CEO, may once again be its low­est paid

5 years ago
People

Saman­tha Truex's Quench Bio calls it quits af­ter fail­ing to solve the Gas­der­min D in­flam­ma­tion puz­zle

5 years ago

An­a­lysts picked the top 4 block­buster con­tenders in the mix — and #1 is a $3.8B coin toss

5 years ago
R&D

Mer­ck dis­card jumps straight to the top of the chart of the most ex­pen­sive drugs in the US at $1M-plus

5 years ago

Gilead­'s Bik­tarvy build its case for long-term use with 4-year da­ta show­ing last­ing HIV sup­pres­sion

5 years ago

Roche with­draws Tecen­triq in blad­der can­cer amid FDA's sweep­ing re­view on ac­cel­er­at­ed ap­provals

5 years ago
FDA+

Fo­cus­ing on the bright side, FDA OKs Roche's Actem­ra for rare lung dis­ease de­spite PhI­II flop

5 years ago
FDA+

Lat­est Mass­Bio re­port shows just how much bio­phar­ma's biggest sec­tor boomed in 2020

5 years ago

Amid back of­fice con­sol­i­da­tion, Gilead ax­es 179 jobs in Cal­i­for­nia

5 years ago

Mer­ck pulls Keytru­da in SCLC af­ter ac­cel­er­at­ed nod. Is the FDA get­ting tough on drug­mak­ers that don't hit their marks?

5 years ago
FDA+

An­gling Pfiz­er, As­traZeneca jumps in­to com­mer­cial PD-(L)1 fight in Chi­na

5 years ago
Deals
China

Pas­cal So­ri­ot cash­es in As­traZeneca’s chips on Mod­er­na for $1.2B cash in­jec­tion

5 years ago

Why not? Sarep­ta’s third Duchenne MD drug sails to ac­cel­er­at­ed ap­proval

5 years ago
FDA+

S&P ex­pects steady ero­sion in Big Phar­ma's cred­it pro­file in 2021 as new M&A deals roll in — but don't un­der­es­ti­mate their un­der­ly­ing strength

5 years ago

Mer­ck takes a swing at the IL-2 puz­zle­box with a $1.85B play for buzzy Pan­dion and its au­toim­mune hope­fuls

5 years ago
Deals

Stephen Hahn makes first post-FDA move, join­ing board of un­der-the-radar Philadel­phia com­pa­ny

5 years ago
People

Lib­tayo scores sec­ond OK in two weeks, this time for front-line NSCLC. Can it take on Keytru­da?

5 years ago
FDA+

A di­ag­nos­tics com­pa­ny com­pletes its phar­ma makeover, re­brand­ing as Fore with Im­munomedics vet at the helm

5 years ago

A year af­ter tri­al fail­ure, As­traZeneca with­draws Imfinz­i's maid­en in­di­ca­tion in blad­der can­cer — but ex­ecs look to the bright side

5 years ago

Ab­b­Vie puts an end to Botox trade se­crets suit, im­pos­es roy­al­ty, li­cense deal on com­peti­tor Evo­lus

5 years ago

Mallinck­rodt be­comes the lat­est vic­tim of the FDA's pan­dem­ic-re­lat­ed de­lays as it push­es off ap­pli­ca­tion for skin graft

5 years ago
FDA+
Manufacturing

5 years lat­er, CAR-T pi­o­neer Kym­ri­ah of­fers jaw-drop­ping ev­i­dence of durable re­mis­sions — even as it still proves a tough sell

5 years ago
R&D

The Covid ef­fect has trig­gered some rad­i­cal changes to the top 50 bio­phar­ma list, bring­ing a whole new group of play­ers in­to the big league

5 years ago
First page Previous page 245246247248249250251 Next page Last page
A service from the Financial Times